For individuals living with early Alzheimer’s disease (AD) and their care partners, managing a chronic condition often involves frequent clinic visits and complex treatment schedules. A major advancement in easing this burden has arrived with the U.S. Food and Drug Administration’s (FDA) approval of LEQEMBI® IQLIK™ (lecanemab-irmb), a subcutaneous injection for maintenance dosing. This approval introduces the first and only anti-amyloid treatment that offers an at-home injection option for patients who have completed their initial intravenous (IV) treatment.

What Is LEQEMBI IQLIK?

LEQEMBI IQLIK™ is a once-weekly subcutaneous autoinjector containing 360 mg/1.8 mL (200 mg/mL) of lecanemab-irmb. Designed for self-administration in about 15 seconds, it is indicated for patients with mild cognitive impairment (MCI) or mild dementia stage of AD (early AD). Treatment begins with 18 months of biweekly IV infusions. After this induction phase, patients may either continue IV infusions once every four weeks or switch to the new weekly injection. The therapy is expected to launch in the U.S. on October 6, 2025.

Why This Matters

• For patients and caregivers: Enables at-home use, saves time, and reduces reliance on infusion centers, helping sustain treatment without disruption.
• For healthcare systems: Frees up infusion capacity for new patients, reducing strain on nursing staff and resources.
• For disease management: Supports continuity of treatment, slowing disease progression, and helping patients maintain cognitive function and independence for longer.

Clinical Validation

The FDA’s decision was based on the Phase 3 Clarity AD open-label extension trial, which showed that switching to weekly subcutaneous dosing preserved the clinical and biomarker benefits of IV infusions. In over 600 patients studied, safety outcomes were comparable, with far fewer systemic reactions (<1% vs. 26% with IV infusions). Mild local skin reactions (about 11%) did not interfere with continued use. Importantly, Amyloid-Related Imaging Abnormalities (ARIA) rates were similar between subcutaneous and IV treatments.

Mechanism of Action

Leqembi works by targeting amyloid plaque and protofibrils, the most toxic beta-amyloid species linked to brain damage and cognitive decline. Clinical studies demonstrated a 27% reduction in cognitive decline at 18 months compared to placebo, with sustained benefits over 48 months.

Safety Considerations

Like other monoclonal antibodies, LEQEMBI carries the risk of ARIA, which can be serious or even fatal. Monitoring with MRI scans is required, and patients with the ApoE ε4 gene variant are at higher risk. Common side effects include headache, mild rash, and nausea, though most occur early in treatment.

Patient Access and Support

Eisai, in partnership with Biogen, will provide patient navigators, co-pay support, and a Patient Assistance Program to ensure access for eligible uninsured and underinsured patients, including those on Medicare.

For resources, education, and support on Alzheimer’s disease, visit talkaboutalz.org.